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Background: This study compared manually delineated gross tumour volume (GTV) and automatically generated
biological tumour volume (BTV) based on fluoro-deoxy-glucose (FDG) positron emission tomography (PET)/CT to
assess the robustness of predefined PET algorithms for radiotherapy (RT) planning in routine clinical practice.
Methods: RT-planning data from 20 consecutive patients (lung- (40%), oesophageal- (25%), gynaecological- (25%)
and colorectal (10%) cancer) who had undergone FDG-PET/CT planning between 08/2010 and 09/2011 were
retrospectively analysed, five of them underwent neoadjuvant chemotherapy before radiotherapy. In addition to
manual GTV contouring, automated segmentation algorithms were applied–among these 38%, 42%, 47% and 50%
SUVmax as well as the PERCIST total lesion glycolysis (TLG) algorithm. Different ratios were calculated to assess the
overlap of GTV and BTV including the conformity index and the ratio GTV included within the BTV.
Results: Median age of the patients was 66 years and median tumour SUVmax 9.2. Median size of the GTVs defined
by the radiation oncologist was 43.7 ml. Median conformity indices were between 30.0–37.8%. The highest amount
of BTV within GTV was seen with the 38% SUVmax algorithm (49.0%), the lowest with 50% SUVmax (36.0%). Best
agreement was obtained for oesophageal cancer patients with a conformity index of 56.4% and BTV within GTV
ratio of 71.1%.
Conclusions: At present there is only low concordance between manually derived GTVs and automatically
segmented FDG-PET/CT based BTVs indicating the need for further research in order to achieve higher volumetric
conformity and therefore to get access to the full potential of FDG-PET/CT for optimization of radiotherapy
planning.
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Over the recent years [18F] FDG-PET imaging has
become a valuable tool in oncology. Based on the higher
sensitivity and specificity compared to conventional
imaging modalities such as CT or MRI alone, PET is
mainly employed for staging.
In addition, PET-CT may also be used as prognostic
and/or predictive tool for radiotherapy [1] or combined
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reproduction in any medium, provided the orhead-and-neck cancer patients has been related to SUV
changes in PET imaging [3]. Several tumour entities have
been described in which data from PET-CT were predict-
ive for pathological response, namely in rectal cancer
[4,5], NSCLC [6] or oesophageal cancer [7,8]. PET/CT
was even described to be complimentarily to a CT scan
and being able to predict early recurrence in breast cancer
[9]. Recent trials on Hodgkin’s disease are at least in part
based on PET imaging and stratification is done according
to PET results. Involved-node radiotherapy has been sug-
gested as tool to further improve the therapeutic ratio by
reducing radiation-induced toxicity [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in radiotherapy providing patho-anatomical information,
predictive data, also information on prognosis and may
be used for adaptive planning, e. g. in head-and-neck can-
cer with anatomical changes during therapy, in future
[11]. Due to its ability to provide complementary informa-
tion (tumour extent and physiology) to MRI and CT,
PET/CT has a potentially important place for radiotherapy
planning [12,13]. In this regard, two aspects have to be
distinguished: Firstly, PET imaging can be used for im-
proved target volume delineation. Secondly, it may also be
used for enhanced dose delivery to the target. For ex-
ample, dose painting by contours (DPBC) consists of cre-
ating an additional PET-based target volume which will
then be treated by a higher dose level [14-18]. In contrast,
dose painting by numbers (DPBN) aims for a locally vary-
ing dose prescription according to the variation of the
PET signal [19].
Many other tumour types are currently under investiga-
tion as PET provides additional information on the tumour
extent, lymph node involvement and putative distant me-
tastases [20,21]. Nevertheless, several problems have to be
solved in future such as the inclusion of dynamic analyses
or the correct thresholding procedures [22].
In order to compare manually delineated GTVs and
automatically generated FDG-PET/CT based BTVs we
retrospectively analysed a series of 20 consecutive patients
who underwent planning PET/CT scanning at a dedicated
PET/CT scanner in treatment position. Tumour types
were restricted to lung cancer, oesophageal cancer and
pelvic cancer mainly consisting of cervical cancer with
macroscopic tumor only. For this purpose, volumetric and




20 consecutive patients received a planning PET/CT
and were categorized into three groups: lung cancer,
oesophageal cancer and solid cancer of the pelvic re-
gion. Scans were performed between 08/2010 and 09/
2011 at the Department of Nuclear Medicine of the
University of Munich. Only patients with a macroscopic
primary tumour and unified GTVs were included into
the retrospective analysis. Five of these patients received
neoadjuvant chemotherapy upfront to radiotherapy,
among these four lung and one oesophageal cancer pa-
tient (median duration from the last cycle to the PET
scan was 2 weeks).
[18F]-FDG PET and PET/CT
Whole-body PET scans were acquired in three-dimensional
(3D) mode extending from the proximal femora to the
base of the skull or from the proximal femora includingthe skull (Biograph 64 TruePoint PET/CT, Siemens
Medical Solutions or GE Discovery 690, GE Healthcare,
Pollards Wood, United Kingdom).
After fasting for at least six hours, blood glucose levels
were measured, a diuretic and an antispasmodic medica-
tion was administered intravenously, followed by bolus ad-
ministration of [18F]-FDG (mean 228 MBq). Scans were
performed with an emptied bladder. The emission se-
quence was initiated at approximately 60 min after intra-
venous injection of the [18F]-FDG. Attenuation scanning
was obtained by CT. Two nuclear medicine physicians
performed a consensus evaluation of the final PET/CT or
PET images using a dedicated software package (Hermes
Hybrid Viewer Version 1.4, Hermes Medical Solution,
Stockholm, Sweden).
Definition and quantitative analysis of tumour volumes
A consultant radiation oncologist without prior know-
ledge of the study delineated all GTVs. All the GTVs were
mainly based on CT imaging and results of PET imaging
were taken into account [23,24] without any systematic
recommendation regarding thresholding or tracer amount
(only the raw data as well as the report of the nuclear
medicine expert were used as guidance for contouring
within the axial CT slices); manually generated GTVs and
their corresponding PTVs were used for treatment pur-
pose in all patients included in this analysis.
A secondary automated lesion segmentation based on
the given [18F]-FDG PET was performed using a dedi-
cated software package (Hybrid Viewer, research ver-
sion, Hermes Medical Solutions, Stockholm, Sweden) in
two different ways: Based on maximal SUV (SUVmax)
thresholding and also according to the total lesion gly-
colysis (TLG) criteria described in PERCIST [25].
For the SUVmax thresholding criteria, separate VOIs
were generated for 38%, 42%, 47% and 50% of SUVmax
whereas these thresholds were chosen empirically based
on literature, phantom studies and own experiences. The
PERCIST TLG criteria were based on [18F]-FDG normal
background activity determined from a 15 ml VOI in the
right hepatic lobe. The outer boundary of the lesion is
equal to 3 standard deviations (SD) above normal-liver
mean SUV. Subsequently all five generated VOIs were
back-projected onto the original CT images used for
therapy planning and exported as DICOM RT structure
sets for comparison with the manually contoured GTV
[25] (an example is shown in Figure 1).
To assess geometric differences between BTV and GTV
the conformity index was computed (expressed as per-
centage). It is defined as the ratio between intersection
and conjunction of both volumes. Additionally the ratio
intersection between GTV/BTV and GTV volumes was
calculated to provide an estimate of accordance with the
manually delineated gold standard.
green:              42%                 38%
red: PERCIST TLG     violet: PERCIST TLG Background 30ml
50% 47%green:
Figure 1 The principle of thresholding is shown for one patient with a NSCLC; red for the PERCIST TLG algorithm, green for different
percentage threshold algorithms.
Table 1 Patient characteristics
Characteristic Patients (N = 20)
Sex
• Male 7 (35%)
• Female 13 (65%)
Median Age [yr] 66 (34–93)
Tumour type
• NSCLC 5 (25%)
• SCLC 3 (15%)
• Cervical cancer 4 (20%)
• Oesophageal cancer 5 (25%)
• Vulvar cancer 1 (5%)
• Rectal cancer 2 (10%)
Median SUVmax 9.2 (3.1–18.2)
Niyazi et al. Radiation Oncology 2013, 8:180 Page 3 of 7
http://www.ro-journal.com/content/8/1/180Statistical analysis
We performed all analyses using the Statistical Package
for Social Sciences (SPSS, Ver. 18.0, SPSS Inc, Chicago,
IL). For descriptive analyses of patients’ characteristics
and volume sizes we used percentages and median
scores. The GTV, and BTV delineation methods were
compared using the Wilcoxon signed-rank test as nu-
merical data were not normally distributed (paired tests);
no corrections for multiple comparisons were performed.
A two-tailed p-value of less or equal than 0.05 was consid-
ered to indicate statistical significance.
Results
Altogether, among the examined 20 patients, eight had
lung cancer (40%), five oesophageal (25%) and seven
(35%) a cancer of the pelvic region (cervical/vulvar or
rectal cancer). Thirteen patients were female (65%) and
median age was 66 years (range, 34–93 years), mean age
66 ± 15 years. Median SUVmax was 9.2 (3.1–18.2), for an
overview see Table 1.
The PET/CT-based, manually contoured, GTV size was
in median 43.7 ml. Concerning different thresholding al-
gorithms, median volume of SUV (38%) was 29.2 ml, me-
dian volume of SUV (42%) 23.8 ml, of SUV (47%) 19.3 ml
and of SUV (50%) 14.5 ml; these values are also shown for
the three defined tumour type subgroups (see Table 2).Interestingly, concerning the volumes there were sig-
nificant differences between the SUV percentage thresh-
olds/region growing algorithm and the manually defined
GTV in all cancer types. Non-significant results were seen
for oesophageal cancer when comparing the PERCIST
TLG result with the GTV defined by the radiation oncolo-
gist, for lung cancer (SUV (38%), SUV (42%)) and pelvic
cancer (SUV (38%), SUV (42%), PERCIST TLG) (see p-
values in Table 2).
Table 2 Different thresholding volumes (median values), corresponding conformity indices and p-values of the




















GTV [ml] 43.7 – – 81.1 – – 34.2 – – 70.4 – –
SUV(38%)
[ml]
29.2 0.04 32.9 30.9 0.33 24.0 15.2 0.04 51.9 28.7 0.24 29.8
SUV(42%)
[ml]
23.8 0.02 30.0 25.4 0.21 25.5 13.8 0.04 47.6 26.0 0.24 27.2
SUV(47%)
[ml]
19.3 <0.001 37.8 17.1 0.04 24.2 12.0 0.04 41.8 22.5 0.03 39.4
SUV(50%)
[ml]
14.5 <0.001 33.3 14.3 0.03 20.5 11.4 0.04 38.7 22.0 0.02 34.5
PERCIST
TLG [ml]
19.8 0.01 35.3 12.8 0.02 30.0 30.3 0.69 56.4 15.3 0.27 24.9
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tio of algorithm-defined volume within the GTV were
evaluated for the whole patient cohort.
The best agreement was determined with a fixed SUV
(38%) threshold: median 49% of this predefined volume
was included within the radiation oncologist’s GTV. The
remaining results are also shown in Table 2. Using the
PERCIST TLG algorithm 43.7% were achieved.
Concerning conformity indices, the best agreement
was determined with a fixed SUV(47%) threshold: median
37.8% overlapped with the GTV. Using the PERCIST
TLG algorithm, the median conformity index was 35.3%.
In a next step, the three subgroups defined by cancer site
were analysed.
For lung cancer, the best agreement was determined
by a fixed SUV (38%) threshold: median 35.4% of this
automatically generated volume was included within the
radiation oncologist’s GTV. Using the PERCIST TLG
growing algorithm 30.2% of the respective BTV was in-
cluded within the manually delineated GTV.
Contrarily, concerning conformity indices, the best
agreement was determined with the PERCIST TLG algo-
rithm: median 37.8% overlapped with the GTV.
For oesophageal cancer, the best agreement was found
using the region-growing threshold: median 71.1% of
this predefined volume was included within the radi-
ation oncologist’s GTV. Concerning conformity indices,
the PERCIST TLG again determined the best agree-
ment: median 56.4% overlap with the GTV.
For pelvic cancer, the best agreement was determined
by the SUV (38%) threshold: median 57.1% of this
predefined volume was included within the radiation on-
cologist’s GTV. Concerning conformity indices, the best
agreement was determined with the SUV (47%) algorithm:
median 39.4% overlap with the GTV. For the remaining
thresholds results were as follows: 29.8% (SUV (38%)),27.2% (SUV (42%)), 34.5% (SUV (50%)) and 24.9%
(PERCIST TLG).
Discussion
Aim of this study was to examine in how far different
PET segmentation algorithms have the potential to re-
place manually defined GTVs. Therefore, altogether 20
patients with cancer types of lung, esophagus or the pel-
vic region were considered, all of them bearing macro-
scopic tumours with no wide-spread disease.
Our data suggest that the general performance was ra-
ther limited with median conformity indices between
30.0–37.8%. The best match with the GTV was obtained
for the subgroup of oesophageal cancer patients with a
conformity index of 56.4% and BTV within GTV ratio of
71.1% whereas potential explanations are reduced move-
ment artifacts and smaller well-defined lesions compared
to lung or pelvic tumours. Especially the performance of
percentage thresholding algorithms was poor–partly as
they are derived from phantom studies (and empirically
from retrospective series) where a SUV of 40–50% of
the maximum was suggested to be appropriate for GTV
contouring of sphere tumours with homogeneously dis-
tributed [18F]-FDG [26]. However, these thresholds hav-
ing been derived under exactly reproducible scientific
conditions had no dependence on SUV variations and
background/noise changes seen in clinical situations.
Regarding these three tumour types, many data are
available and studies are ongoing. However, most of
them have not included a dedicated planning PET/CT
but a separate scan which bears the disadvantage of co-
registration errors.
PET/CT has early been shown to improve accuracy of
target volume delineation for treatment optimization in
NSCLC [27], but taking a 40% SUVmax threshold has
been shown to be not appropriate for GTV definition
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volume changes from GTV [CT] to GTV [PET/CT] were
lower for the nuclear medicine expert than for the radi-
ation oncologists, suggesting a lower impact of PET/CT in
target volume delineation for the nuclear medicine expert
than for the radiation oncologists [29]; this observation is
probably due to the radiation oncologist’s experience on
the natural tumour spread and thus a tendency to extend
the respective GTV.
Besides an improved target volume definition, PET has
been shown to reduce radiation treatment volumes caused
by the avoidance of PET negative mediastinal lymph nodes
in NSCLC patients. Thus it reduces toxicity with the same
radiation dose or enables radiation dose escalation with the
same toxicity. PET also reduces interobserver variability
[24,30] for delineating tumours and opens perspectives for
more automated delineation parts in radiation treatment
planning. Despite all inherent limitations present FDG-
PET/CT scans are frequently used in routine clinical prac-
tice for NSCLC [31,32].
Concerning the pelvic region, with a constantly ad-
vancing body of evidence and increasing availability,
applications of PET/CT in colorectal and cervical can-
cer are likely to emerge in therapy response assessment
[33], radiotherapy planning, use of novel tracers and
one-stop-shop imaging techniques such as iodinated
contrast-enhanced PET/CT [34,35].
In a recent study comparing MRI and PET/CT in cer-
vical cancer patients it could be shown that the mean dif-
ference between MRI and PET volumes was least with
30% SUVmax threshold which is similar to our results [36].
Last but not least, when combined PET/CT was used
for radiotherapy treatment planning in oesophageal can-
cer, there have been alterations to the delineation of
tumour volumes when compared to CT alone, with the
potential to avoid geographical misses of tumour [37].
This indicates a clinical role for FDG/PET in radiother-
apy planning for oesophageal cancer [38].
Related to the retrospective nature of our study with a
relatively small heterogeneous patient cohort several key
limitations have to be stated.
Firstly, due to subjective adaptation of the manually
derived GTVs (where inter- and intra-observer variabil-
ity were not taken into account), these may be larger
than the real tumour extent. Secondly, since in 5/20
cases neoadjuvant chemotherapy was applied the given
post-therapeutic tissue alterations may result in consid-
erable problems for any auto-segmentation algorithm.
Thirdly, co-registration was performed manually in a
small number of cases leaving room for slightly impre-
cise correspondence of PET and CT information.
Furthermore, several minor problems have to be taken
into account: Macroscopic tumour next to organs or struc-
tures with naturally higher glucose metabolism/uptakebears further problems for exact auto-segmentation as
these structures have to be masked out manually. Add-
itionally, distant secondary GTVs such as lymph node me-
tastases may create problems related to their different FDG
uptake pattern where a local background would be more
suitable [39].
Thus, automated segmentation may indeed currently
be used to complement the delineation process. But at
present, none of the tested algorithms is able to fully re-
place the process of manual target volume definition
and critical editing of any given PET signal.
From a radiation oncologist’s point of view the most
immanent need would be the development of robust
algorithms for the reliable definition of macroscopic
tumour extent or adequate processing constraints to
generate CTV [39,40] or PTV [41]. The most promising
algorithms are background- and metabolically corrected
algorithms such as the PERCIST TLG algorithm.
In the meantime, the use of PET for planning purposes
requires a very close interaction of radiation oncologists,
nuclear medicine experts and diagnostic radiologists for
individual treatment planning. In this regard, several lo-
gistic issues have to be solved adequately: Who sets the
contour at which time point, and how can all the avail-
able diagnostic information properly be integrated dur-
ing the planning process?
Conclusions
All in all, there is only low concordance between manu-
ally derived GTVs and automatically segmented FDG-
PET/CT based BTVs at present indicating the need for
further research in order to achieve higher volumetric con-
formity. Nevertheless, our data suggest that FDG-PET/CT
may be regarded as an important tool for optimization of
radiotherapy planning.
Competing interests
Andreas Elsner due to employment. The remaining authors declare that they
have no competing interests.
Authors’ contributions
UG, MH, AE, SL, FM, CB & MN planned, coordinated and conducted the
study. MN analysed the treatment planning data, fused imaging data set,
performed associated statistics and wrote the manuscript. SL, AE & MH
performed PET imaging, provided the standard for PET-contouring, the fused
data sets and contributed parts to the manuscript. All authors read, critically
revised and approved the final manuscript.
Author details
1Department of Radiation Oncology, University of Munich, Marchioninistr. 15,
81377, Munich, Germany. 2Department of Nuclear Medicine, University of
Munich, Marchioninistr. 15, 81377, Munich, Germany. 3Hermes Medical
Solutions, Skeppsbron 44, 11130, Stockholm, Sweden.
Received: 30 April 2013 Accepted: 9 July 2013
Published: 12 July 2013
References
1. Parlak C, Topkan E, Onal C, Reyhan M, Selek U: Prognostic value of gross
tumor volume delineated by FDG-PET-CT based radiotherapy treatment
Niyazi et al. Radiation Oncology 2013, 8:180 Page 6 of 7
http://www.ro-journal.com/content/8/1/180planning in patients with locally advanced pancreatic cancer treated
with chemoradiotherapy. Radiat Oncol 2012, 7:37.
2. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ: PET-CT for
radiotherapy treatment planning and response monitoring in solid
tumors. Nat Rev Clin Oncol 2011, 8(4):233–242.
3. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P:
Prediction of outcome in head-and-neck cancer patients using the
standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int J
Radiat Oncol Biol Phys 2004, 59(5):1295–1300.
4. de Geus-Oei L-F, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen
WJG: Monitoring and predicting response to therapy with (18)F-FDG PET
in colorectal cancer: a systematic review. J Nucl Med 2009, 50:43S–54S.
5. Goldberg N, Kundel Y, Purim O, Bernstine H, Gordon N, Morgenstern S,
Idelevich E, Wasserberg N, Sulkes A, Groshar D, et al: Early prediction of
histopathological response of rectal tumors after one week of
preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A
prospective clinical study. Radiat Oncol 2012, 7:124.
6. Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W,
Stamatis G, Gauler T, Antoch G, et al: Value of 18F-fluoro-2-deoxy-D-glucose-
positron emission tomography/computed tomography in non-small-cell
lung cancer for prediction of pathologic response and times to relapse
after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006, 12(1):97–106.
7. Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F:
Curative treatment of oesophageal carcinoma: current options and
future developments. Radiat Oncol 2011, 6:55.
8. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD,
Lee SW, et al: FDG-PET in the prediction of pathologic response after
neoadjuvant chemoradiotherapy in locally advanced, resectable
esophageal cancer. Int J Radiat Oncol Biol Phys 2005, 63(4):1053–1059.
9. Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C,
Saladini G, Sotti G: Tumour markers and FDG PET/CT for prediction of
disease relapse in patients with breast cancer. Eur J Nucl Med Mol
Imaging 2011, 38(2):293–301.
10. Kobe C, Dietlein M, Fuchs M: Interpretation and validation of interim
positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma
2010, 51(3):552–553.
11. Gregoire V, Jeraj R, Lee JA, O'Sullivan B: Radiotherapy for head and neck
tumours in 2012 and beyond: conformal, tailored, and adaptive?
Lancet Oncol 2012, 13(7):e292–e300.
12. Yaromina A, Zips D: Bio-IGRT. Biologically-adapted, forming truncated
Radiotherapy. Nuklearmedizin 2010, 49(6A):S50–S52.
13. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H,
Gregoire V: Tumor volume in pharyngolaryngeal squamous cell
carcinoma: comparison at CT, MR imaging, and FDG PET and validation
with surgical specimen. Radiology 2004, 233(1):93–100.
14. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, Galldiks N,
Coenen HH, Kaiser HJ, Langen KJ, et al: Integrated boost IMRT with FET-
PET-adapted local dose escalation in glioblastomas. Results of a
prospective phase II study. Strahlenther Onkol 2012, 188(4):334–339.
15. Fodor A, Fiorino C, Dell'Oca I, Broggi S, Pasetti M, Cattaneo GM, Gianolli L,
Calandrino R, Di Muzio NG: PET-guided dose escalation tomotherapy in
malignant pleural mesothelioma. Strahlenther Onkol 2011,
187(11):736–743.
16. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, Caffaro M, Winz
OH, Krohn T, Mottaghy FM, et al: Dose-escalation using intensity-
modulated radiotherapy for prostate cancer–evaluation of quality of life
with and without (18)F-choline PET-CT detected simultaneous integrated
boost. Radiat Oncol 2012, 7:14.
17. Niyazi M, Bartenstein P, Belka C, Ganswindt U: Choline PET based dose-
painting in prostate cancer–modelling of dose effects. Radiat Oncol 2010,
5:23.
18. Wurschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M: [18F]
fluoroethylcholine-PET/CT imaging for radiation treatment planning of
recurrent and primary prostate cancer with dose escalation to PET/CT-
positive lymph nodes. Radiat Oncol 2011, 6:44.
19. Thorwarth D, Geets X, Paiusco M: Physical radiotherapy treatment
planning based on functional PET/CT data. Radiother Oncol 2010,
96(3):317–324.
20. Schober O: PET/CT in head and neck squamous cell carcinoma with an
unknown primary: significant diagnostic benefit in a prospective clinical
trial. Strahlenther Onkol 2012, 188(7):637–638.21. MacDonald SL, Mulroy L, Wilke DR, Burrell S: PET/CT aids the staging of
and radiotherapy planning for early-stage extranodal natural killer/T-cell
lymphoma, nasal type: a case series. Radiat Oncol 2012, 6:182.
22. Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA,
Boellaard R: Impact of [(1)(8)F]FDG PET imaging parameters on automatic
tumour delineation: need for improved tumour delineation
methodology. Eur J Nucl Med Mol Imaging 2011, 38(12):2136–2144.
23. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, Hellwig D,
Niewald M, Ukena D, Kirsch CM, et al: 18F-deoxyglucose positron emission
tomography (FDG-PET) for the planning of radiotherapy in lung cancer:
high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999,
44(3):593–597.
24. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lutolf UM,
Steinert HC, Von Schulthess GK: Radiation treatment planning with an
integrated positron emission and computer tomography (PET/CT): a
feasibility study. Int J Radiat Oncol Biol Phys 2003, 57(3):853–863.
25. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST:
evolving considerations for PET response criteria in solid tumors. J Nucl
Med 2009, 50(Suppl 1):122S–150S.
26. Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, Fukugami S,
Asakawa I, Tamamoto T, Hasegawa M: Phantom study on radiotherapy
planning using PET/CT–delineation of GTV by evaluating SUV. J Radiat
Res 2010, 51(2):157–164.
27. Greco C, Rosenzweig K, Cascini GL, Tamburrini O: Current status of PET/CT
for tumour volume definition in radiotherapy treatment planning for
non-small cell lung cancer (NSCLC). Lung Cancer 2007, 57(2):125–134.
28. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube
C, Kirsch CM: Comparison of different methods for delineation of 18F-
FDG PET-positive tissue for target volume definition in radiotherapy of
patients with non-small cell lung cancer. J Nucl Med 2005,
46(8):1342–1348.
29. Hanna GG, Carson KJ, Lynch T, McAleese J, Cosgrove VP, Eakin RL, Stewart
DP, Zatari A, O'Sullivan JM, Hounsell AR: 18F-fluorodeoxyglucose positron
emission tomography/computed tomography-based radiotherapy target
volume definition in non-small-cell lung cancer: delineation by radiation
oncologists vs. joint outlining with a PET radiologist? Int J Radiat Oncol
Biol Phys 2010, 78(4):1040–1051.
30. Vees H, Casanova N, Zilli T, Imperiano H, Ratib O, Popowski Y, Wang H,
Zaidi H, Miralbell R: Impact of 18F-FDG PET/CT on target volume
delineation in recurrent or residual gynaecologic carcinoma.
Radiat Oncol 2012, 7:176.
31. De Ruysscher D: PET-CT in radiotherapy for lung cancer. Positron Emission
Tomography 2011, 727:53–58.
32. De Ruysscher D, Nestle U, Jeraj R, Macmanus M: PET scans in radiotherapy
planning of lung cancer. Lung Cancer 2012, 75(2):141–145.
33. Brooks FJ, Grigsby PW: Current measures of metabolic heterogeneity
within cervical cancer do not predict disease outcome. Radiat Oncol
2011, 6:69.
34. Chowdhury FU, Shah N, Scarsbrook AF, Bradley KM: (18)F FDG PET/CT
imaging of colorectal cancer: a pictorial review. Postgrad Med J 2010,
86(1013):174–182.
35. Salem A, Salem AF, Al-Ibraheem A, Lataifeh I, Almousa A, Jaradat I:
Evidence for the use PET for radiation therapy planning in patients
with cervical cancer: a systematic review. Hematol Oncol Stem Cell Ther
2011, 4(4):173–181.
36. Upasani MN, Mahantshetty UM, Rangarajan V, Purandare N, Merchant N,
Thakur M, Engineer R, Chopra S, Shrivastava SK: 18-fluoro-deoxy-glucose
positron emission tomography with computed tomography-based gross
tumor volume estimation and validation with magnetic resonance
imaging for locally advanced cervical cancers. Int J Gynecol Cancer 2012,
22(6):1031–1036.
37. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, Pitman A, Lau EW,
MacManus M, Binns D, et al: A prospective study to evaluate the impact
of FDG-PET on CT-based radiotherapy treatment planning for
oesophageal cancer. Radiother Oncol 2006, 78(3):254–261.
38. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N,
Hiele M, Flamen P: Is there a role for FGD-PET in radiotherapy planning in
esophageal carcinoma? Radiother Oncol 2004, 73(3):269–275.
39. Ciernik IF, Brown DW, Schmid D, Hany T, Egli P, Davis JB: 3D-segmentation
of the 18F-choline PET signal for target volume definition in radiation
therapy of the prostate. Technol Cancer Res Treat 2007, 6(1):23–30.
Niyazi et al. Radiation Oncology 2013, 8:180 Page 7 of 7
http://www.ro-journal.com/content/8/1/18040. Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V,
Picchio M, Landoni C, Fazio F: Feasibility of [18F]FDG-PET and
coregistered CT on clinical target volume definition of advanced non-
small cell lung cancer. Q J Nucl Med Mol Imaging 2005, 49(3):259–266.
41. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G: Automated functional
image-guided radiation treatment planning for rectal cancer. Int J Radiat
Oncol Biol Phys 2005, 62(3):893–900.
doi:10.1186/1748-717X-8-180
Cite this article as: Niyazi et al.: Automated biological target volume
delineation for radiotherapy treatment planning using
FDG-PET/CT. Radiation Oncology 2013 8:180.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
